CCND1 and prostate carcinoma: Our earlier studies using gnetin C in prostate cancer cell lines and xenografts had shown potent inhibition of the MTA1 and MTA1-associated downstream signaling targets, including proto-oncogene 2 (ETS2), Cyclin D1, and Notch 2 [31,35].